Clinical features and aCGH analysis of one child with Phelan-McDermid syndrome #br#
ZHANG Hongyun, WANG Xi
(Rehabilitation Department in Children’s Hospital of Chongqing Medical University, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Pediatrics, Chongqing International Science and Technology Cooperation Center for Child Development and Disorders, Chongqing 400014, China)
[1] 林庆. 2004年全国小儿脑性瘫痪专题研讨会纪要 [J]. 中华儿科杂志，2005，43（4）：261-262. [2] Phelan K1，McDermid HE.The 22q13.3 Deletion Syndrome (Phelan-McDermid Syndrome) [J]. Mol Syndromol，2011，2(3-5)：186-201. [3] Watt JL，Olson IA，Johnston AW，et al.A familial pericentric inversion of chromosome 22 with a recombinant subject illustrating a ‘pure’ partial monosomy syndrome [J]. J Med Genet，1985，22 (4)：283-287. [4] Bonaglia MC，Giorda R，Mani E，et al. Identification of a recurrent breakpoint within the SHANK3 gene in the 22q13.3 deletion syndrome [J].J Med Genet，2006，43(10)：822-828. [5] Cusmano-Ozog K，Manning MA，Hoyme HE. 22q13.3 deletion syndrome：a recognizable malformation syndrome associated with marked speech and language delay [J]. Am J Med Genet C Semin Med Genet，2007，145C(4)：393-398. [6] Dhar SU，del Gaudio D，German JR，et al. 22q13.3 deletion syndrome：clinical and molecular analysis using array CGH [J]. Am J Med Genet A，2010，152A(3)：573-581. [7] Phelan MC，Stapleton GA，Rogers RC. The management of genetic syndromes [M]. John Wiley Sons，2010:258-297. [8] 付敏，邹小兵，章钧，等. 中国Phelan-McDermid 综合征1例患儿的临床及分子遗传学分析 [J]. 中华实用儿科临床杂志，2013，28（8）：586-588. [9] Durand CM，Betancur C，Boeckers TM，et al. Mutations in the gene encoding the synaptic scaffolding protein SHANK3 are associated with autism spec-trum disorders [J]. Nat Ge-net ，2007，39(1)：25-27 . [10] Manning MA，Cassidy SB，Clericuzio C，et al. Terminal 22q deletion syndrome：a newly recognized cause of speech and language disability in the autism spectrum [J]. Pediatrics，2004，114(2)：451-457. [11] Phelan K. 22q13.3 deletion syndrome [M/OL] Pagon RA，Bird TD，Dolan CR，et al. GeneReviews [2014-02-19] http：//www.ncbi.nlm.nih.gov/books/NBK1198/. [12] Wilson HL，Wong AC，Shaw SR，et al. Molecular characte-rization of the 22q13 deletion syndrome supports the role of haploinsufficiency of SHANK3/PROSAP2 in the major neurological symptoms [J]. J Med Genet，2003，40：(8) 575-584. [13] Bonaglia MC，Giorda R，Borgatti R，et al. Disruption of the ProSAP2 gene in at(12; 22)(q24.1;q13.3) is associated with the 22q13.3 deletion syndrome [J]. Am J Hum Genet ，2001，69（2）：261-268. [14] Sarasua SM， Dwivedi A， Boccuto L，et al. Association between deletion size and important phenotypes expands the genomic region of interest in Phelan-McDermid syndrome (22q13 deletion syndrome) [J]. J Med Genet， 2011，48(11)：761-766. [15] Sarasua SM， Dwivedi A， Boccuto L，et al. 22q13.2q13.32 genomic regions associated with severity of speech delay，developmental delay，and physical features in Phelan-McDermid syndrome [J]. Genet Med， 2014，16(4)：318-328. [16] Shcheglovitov A， Shcheglovitova O， Yazawa M， et al. SHANK3 and IGF1 restore synaptic deficits in neurons from 22q13 deletion syndrome patients [J]. Nature，2013，503(7475)：267-271.
